Location of Repository

Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends

By Stanislaw Gorski, Simon M Collin, Koert Ritmeijer, Kees Keus, Francis Gatluak, Marius Mueller and Robert N Davidson

Abstract

BACKGROUND: Risk factors associated with L. donovani visceral leishmaniasis (VL; kala azar) relapse are poorly characterized. METHODS: We investigated patient characteristics and drug regimens associated with VL relapse using data from Médecins Sans Frontières - Holland (MSF) treatment centres in Southern Sudan. We used MSF operational data to investigate trends in VL relapse and associated risk factors. RESULTS: We obtained data for 8,800 primary VL and 621 relapse VL patients treated between 1999 and 2007. Records of previous treatment for 166 VL relapse patients (26.7%) were compared with 7,924 primary VL patients who had no record of subsequent relapse. Primary VL patients who relapsed had larger spleens on admission (Hackett grade >or=3 vs 0, odds ratio (OR) for relapse = 3.62 (95% CI 1.08, 12.12)) and on discharge (Hackett grade >or=3 vs 0, OR = 5.50 (1.84, 16.49)). Age, sex, malnutrition, mobility, and complications of treatment were not associated with risk of relapse, nor was there any trend over time. Treatment with 17-day sodium stibogluconate/paromomycin (SSG/PM) combination therapy vs 30-day SSG monotherapy was associated with increased risk of relapse (OR = 2.08 (1.21, 3.58)) but reduced risk of death (OR = 0.27 (0.20, 0.37)), although these estimates are likely to be residually confounded. MSF operational data showed a crude upward trend in the proportion of VL relapse patients (annual percentage change (APC) = 11.4% (-3.4%, 28.5%)) and a downward trend in deaths (APC = -18.1% (-22.5%, -13.4%)). CONCLUSIONS: Splenomegaly and 17-day SSG/PM vs 30-day SSG were associated with increased risk of VL relapse. The crude upward trend in VL relapses in Southern Sudan may be attributable to improved access to treatment and reduced mortality due to SSG/PM combination therapy

Year: 2010
DOI identifier: 10.1371/journal.pntd.0000705
OAI identifier: oai:fieldresearch.msf.org:10144/114020
Provided by: MSF Field Research
Journal:

Suggested articles

Preview

Citations

  1. (2006). A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
  2. (2004). Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.
  3. (2003). Emergence or re-emergence of visceral leishmaniasis
  4. (1996). Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources.
  5. (2001). Leishmaniasis in Sudan. Visceral leishmaniasis.
  6. (2006). Unseen Kala-azar deaths in south Sudan
  7. (2003). Visceral leishmaniasis and HIV in Tigray,
  8. (2002). Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.